Search This Blog

Sunday, September 13, 2020

Laurus Labs Limited, Power bank in Pharma Sector

 Laurus Labs Limited has outperformed the stock market and pharma sector, Pharma Sector is  in flavour since the COVID-19 pandemic and pharma sector has outperformed all indices and in Pharma sector laurus Labs has outperformed the pharma sector by a big way.

Laurus labs limited share has given returns of 300% in last 3 months. Share is trading around Rs. 1260 per share which was  trading at Rs. 450 levels around three months ago. 

Business Model:-

Mr. Satyanarayana Chava, Founder & CEO of the Laurus Labs Limited
Laurus Labs is having headquarters in Hyderabad and it is an Indian pharmaceutical company. This company is involved in the research and development of active pharmaceutical ingredients (API) for anti-retrovirals, hepatitis C drugs, oncology, cardiovascular, anti-diabetics, anti-asthma, and gastroenterology
This Pharma company is the world's largest third party API supplier for anti-retrovirals.
•During Covid-19 Pandemic In March 2020, Laurus Labs received USFDA approval to market hydroxychloroquine sulfate tablets, which earlier are used in treatment by USA  for COVID-19 treatment. 
The company announced that it would supply hydroxychloroquine to its US partner Rising Pharma for clinical trials of preventive treatment of COVID-19.

Financial results:-

From Financial you can see that how its profitability is getting improved quarter on quarter in 1 year profitability has been increase from Rs. 15 crores to Rs. 171 crores i.e. Jump of more than 10 times in profitability. 
Also you can see that sales has been increased from Rs. 550 crores to Rs. 974 crores.
Shareholding:-


From Shareholding you can see that Promoters are holding very good percentage of Shareholding and Pledged share has been reduced from 45.22 % to 31.56%. Further FII are very much bullish in this as they have raised stake in company from 11.29% to 16.06% from last quarter although DII has reduced the stake in company from 41.53% to 32.39%.

Comparative with Lupin and Aurobindo Pharma:-



From above you can see that Laurus Labs has outperformed both Lupin and Aurobindo Pharma.


For more details visit link as below:-



1 comment:

  1. I Like to add one more important thing here, The Active Pharmaceutical Ingredients Market is expected to be around US$ 238.5 Billion by 2025 at a CAGR of 6% in the given forecast period.

    ReplyDelete

Note: Only a member of this blog may post a comment.